MDM2 and ovarian serous adenocarcinoma: In addition, almost 4% of high grade serous ovarian cancers nevertheless have wild-type TP53 and these mostly have BRCA1/2 mutation or other HRD status [42], rendering them sensitive to both MDM2 inhibitors and rucaparib and therefore likely to benefit from the combined treatment.